A new peer reviewed report published by the Division of Hematology and Oncology, Department of Medicine at University of Alabama shows that the bone health drug zoledronic acid may be able to inhibit tumor growth in mesothelioma patients. The study, titled, A pilot study of zoledronic acid in the treatment of patients with advanced malignant pleural mesothelioma, focused on eight patients who had progressed on prior treatments or had not received systemic therapy due to poor performance status.
The demographics of the eight patients included all males (7 Caucasian and 1 African-American) with a median age of 62 years (age range 49–77). As a standalone treatment the bone health drug had only a modest impact with a composite response rate of 12.5 percent and a clinical benefit rate (response and stability of the disease) of 37.5 percent.
Despite the modest impact as a standalone treatment the University of Alabama Researchers maintain hope that when combined with other therapies, zoledronic acid still may be valuable as a form of multimodal treatment. Lead author of the report, Muhammad Omer Jamil wrote, “Our findings suggest that zoledronic acid has single-agent activity in [malignant pleural mesothelioma] treatment. Zoledronic acid can mitigate angiogenesis at subcellular level by mevalonate pathway inhibition and is beneficial in antitumor therapy.”
The Paul Law Firm advocates for victims of asbestos-related diseases. If you or a loved one is suffering from mesothelioma, call the Paul Law Firm. With over 2.5 billion dollars collected for victims of asbestos exposure, we have the knowledge and the experience to fight for you. We also understand that fighting doesn’t just happen in the courtroom. It also happens in a lab where we are fighting for a cure. Check out the Mesothelioma Research Foundation of America here.
Call us today at 1-855 88 LEGAL (885-3425) or contact us online to discuss your case with one of our experienced mesothelioma lawyers